Oncopeptides AB (publ) provided sales guidance for the first quarter of 2024. The company expected net sales to amount to SEK 5.1 million (SEK 1.1 million).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.905 SEK | -2.35% | -0.17% | -62.08% |
15/04 | Oncopeptides AB Secures National Reimbursement for Pepaxti in Spain | CI |
04/04 | Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-62.08% | 58.44M | |
+2.97% | 108B | |
+10.21% | 105B | |
+1.57% | 23.46B | |
-12.77% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-6.50% | 17.19B | |
+6.00% | 13.99B | |
+37.20% | 12.53B |
- Stock Market
- Equities
- ONCO Stock
- News Oncopeptides AB
- Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024